Landmark Research in ACTN Confirms Low-Field MRI Feasibility in Outpatient Clinics for People Living with HIV (PWH)
A critical challenge in global healthcare is ensuring equitable access to advanced diagnostic tools, especially for populations facing socioeconomic and systemic barriers. A recent paper published in ACTN by researchers from Harvard Medical School and Mass General Brigham confirms that portable, ultra-low-field MRI (Hyperfine’s Swoop®) provides a viable solution for neuroimaging in People Living with HIV (PWH).
Bridging the Gap in Neurological Care
Historically, routine brain monitoring for PWH—essential for detecting atrophy and preventing dementia as the population ages—has been limited by the lack of access to high-field MRI, particularly in resource-constrained or remote settings.
The study, led by Annabel Sorby-Adams, PhD, and published in the Annals of Clinical and Translational Neurology (ACTN), demonstrates the feasibility of using the portable, low-field MRI (LF-MRI) system directly in an outpatient clinic setting. Crucially, this was coupled with a machine learning (ML) segmentation algorithm (WMH-SynthSeg) to precisely assess brain volumes and white matter hyperintensities (WMH).
Key Clinical and Research Findings
The research successfully validated the LF-MRI’s ability to capture nuanced subcortical changes, offering key insights into brain health among PWH:
- Regional Atrophy Detection: LF-MRI successfully detected discriminant atrophy in the caudate and putamen regions of PWH, areas known to be vulnerable during periods of uncontrolled viral replication. This demonstrates the sensitivity of the portable system.
- Hippocampal Volume Comparisons: Hippocampal volumes in PWH were comparable to those observed in cohorts with mild cognitive impairment (MCI) due to Alzheimer’s disease and vascular comorbidities.
- Feasibility and Accessibility: The study confirms that LF-MRI is not only feasible in an outpatient setting but, when combined with ML segmentation, enables the earlier detection of atrophy in at-risk populations.
Photo credits : Annabel Sorby-Adams
Democratizing Brain Health
The significance of this work extends far beyond the study cohort. By confirming that LF-MRI and AI can accurately assess regional atrophy in an accessible outpatient setting, the Harvard team has provided a blueprint for future adoption:
“Together, these results highlight how portable MRI and AI can expand access to neuroimaging and enable earlier detection of brain changes in populations that have historically faced barriers to care.”
UpCare commends the researchers for this pivotal work, which reinforces the collective mission to leverage innovation—like the Hyperfine Swoop® system—to enable equitable and sustainable neuroimaging access worldwide.
Want to learn more?
Click below to read the original ACTN paper
Go back to News & Updates page.
Questions
about integrating this technology?
Contact the UpCare team for more information.